Key facts
- Basecamp Research’s last known valuation is $177.0M (Oct 2024).
- It has raised $84.3M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Microsoft for Startups, True Ventures, S32, Hummingbird Ventures, Redalpine — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Basecamp Research
- ·The full record, as it builds
Funding rounds
No funding rounds for Basecamp Research are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Basecamp Research
Developer of a biological-design platform designed to explore and recreate the full complexity of natural biodiversity. The company's platform uses a massive, ethically-sourced biological knowledge graph and AI-driven tools to map biodiversity at scale, reconstruct multiple novel protein sequences, model full biological context, and design new proteins and genomes, enabling research and biotech organizations to develop novel therapeutics, food, agriculture, and other biologically-derived products with innovation and potential beyond traditional methods.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 48
- Website
- basecamp-research.com/
- Ownership
- Privately Held (backing)
Basecamp Research doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Basecamp Research shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Basecamp Research in its N-PORT filings yet. We sweep new filings monthly.